• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Correspondence: Resurgence of Mycoplasma pneumonia by macrolide-resistant epidemic clones in China - The Lancet

Mary Wilson

Well-known member
Published: January 17, 2024

DOI:https://doi.org/10.1016/S2666-5247(23)00405-6

Heng Li, Shengkai Li, Huajiang Yang, Zhengrong Chen, Zhemin Zhou

In The Lancet Microbe, Patrick M Meyer Sauteur and colleagues1 reported about a delayed re-emergence of Mycoplasma pneumoniae after the COVID-19 pan- demic restrictions. According to initial study findings, China is currently facing a concurrent outbreak of paediatric respiratory diseases, particularly the macrolide-resistant M pneumoniae(MRMP)outbreak.2 Onthebasisofmore than 30000 PCR tests and bronchos- copy findings (appendix p 3) in a paediatric hospital in east China from 2017 to 2023, we found a pronounced re-emergence of M pneumoniae, with up to 50% positive cases noted since July, 2023 (appendix p 2), compared with a lower incidence of positive cases ranging from 10% to 20% during the COVID-19 period (2020–22). ...

https://www.thelancet.com/action/showPdf?pii=S2666-5247(23)00405-6
 
Back
Top